Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast 2032
DelveInsight’s Immune thrombocytopenia Market Insights report provides a thorough understanding of current treatment practices, emerging drugs, Immune thrombocytopenia market share of the individual therapies, current and forecasted Immune thrombocytopenia market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Immune thrombocytopenia Overview
Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of immune thrombocytopenia, stem from a low platelet count leading to excessive bleeding.
Do you know about Immune thrombocytopenia Market Share?
Some of the major highlights of the Immune thrombocytopenia market report
- Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are female as compared to male.
- DelveInsight’s estimations suggests that the total Immune thrombocytopeniaprevalent population in the seven major markets was approximately 184,676 in 2020.
- The totalImmune thrombocytopenia diagnosed prevalent cases in the 7MM was estimated to be approximately 150,612 in 2020.
- Immune thrombocytopenia key players included such as Octapharma USA, Amgen, CSL Behring, Dova Pharmaceuticals, Rigel Pharmaceuticals, Zenyaku Kogyo/Biogen Idec, Novartis, Bio Products Laboratory’s, Takeda Pharmaceutical Company Limited, AstraZeneca, Biotest, and several others.
- Immune thrombocytopenia therapies included such as Octagam, Nplate (AMG-531), Privigen, Rhophylac, Doptelet (Avatrombopag), Tavalisse (fostamatinib disodium hexahydrate), Rituximab, Promacta (eltrombopag), Gammaplex, Takecab, Nexium Capsules, and several others.
Immune thrombocytopenia Types
The two main types of ITP are acute (short term) and chronic (long term). ITP is also categorized as primary and secondary based on the cause of the disease. ITP in the absence of other causes or disorders that may be associated with the thrombocytopenia is known as primary ITP, whereas, secondary ITP refers to immune-mediated thrombocytopenia with an underlying cause, including drug-induced, or associated with systemic illness (e.g., systemic lupus erythematosus, infection [e.g., HIV], immune deficiency [e.g., common variable immunodeficiency or autoimmune lymphoproliferative syndrome], and other causes).
Immune Thrombocytopenia Diagnosis
The diagnosis of ITP is made by excluding other causes of thrombocytopenia, including certain medications or disorders that affect the bone marrow and reduce platelet production, such as acute leukemia and aplastic anemia. It is diagnosed by complete blood count (CBC), additional blood and urine tests to measure bleeding time and detect possible infections, careful examination of medical history, and/or bone marrow aspiration.
Immune Thrombocytopenia (ITP) Treatment
The major goal for the treatment of ITP is to provide a platelet count that prevents major bleeding rather than correcting the platelet count to normal levels. The management of ITP varies widely and current international guidelines recommend several first- and second-line options, including some medicinal products that have not been approved in the EU for this particular condition.
Immune Thrombocytopenia Market Drugs
- Nplate (AMG-531): Amgen
- Doptelet (Avatrombopag): Dova Pharmaceuticals
- Tavalisse (fostamatinib disodium hexahydrate): Rigel Pharmaceuticals
Immune Thrombocytopenia Emerging Drugs
- BT-595: Biotest
- Rozanolixizumab: UCB Biopharma
- Efgartigimod (ARGX-113): Argenx
Immune Thrombocytopenia Market Outlook
The US Food and Drug Administration (FDA) has approved three Thrombopoietin receptor agonist (TPO-RA) therapies: romiplostim (Nplate), eltrombopag (Promacta), and avatrombopag (Doptelet). For Europe and Japan, only two TPO-RAs is approved, i.e., Nplate and Promacta. Promacta and Nplate will lose their patent in 2022 in the US, whereas, in Europe and Japan, Nplate loses the patent in 2019 and Promacta will lose patent in 2025. Due to their patent expiry, it is expected that the approval of Doptelet is likely to cover a major patient pool.
From 2023, the market value will start declining due to the patent expiration and subsequent launch of generic/biosimilar of Nplate and Promacta. So till 2022 Doptelet will continue to compete with both these drugs and after the patent expiry, Doptelet will not have any competitor in the market. Apart from TPO-RAs, various drugs like, Takecab and Nexium capsules are approved in Japan that is indicated for the eradication of Helicobacter pylori in patients with idiopathic thrombocytopenic purpura.
Get in-depth details on Immune Thrombocytopenia Market Size
Table of content
1. Key Insights
2. Executive Summary of Immune Thrombocytopenia
3. SWOT Analysis for Immune Thrombocytopenia
4. Immune Thrombocytopenia (ITP) Market Overview at a Glance
5. Immune Thrombocytopenia (ITP): Disease Background and Overview
6. Epidemiology and Patient Population
7. Country Wise-Epidemiology of Immune Thrombocytopenia (ITP)
8. Treatment and Management of Immune Thrombocytopenia (ITP)
9. Patient Journey of Immune Thrombocytopenia
10. Unmet Needs
11. Key Endpoints of Immune Thrombocytopenia
12. Marketed Drugs
13. Emerging Drugs
14. Attribute Analysis of Immune Thrombocytopenia Therapies
15. Immune Thrombocytopenia (ITP): Seven Major Market Analysis
16. Market Outlook: The United States
17. Market Outlook: Europe
18. Market Outlook: Japan
19. Access and Reimbursement Overview for Current and Future Therapies
20. Market Drivers
21. Market Barriers
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
